Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Boston Scientific stock trades at EUR 40.89 ahead of October 28 results

Analyst downgrade Earnings report AI-generated analysis

πŸ“… Boston Scientific is scheduled to release third-quarter results before the market opens on October 28, 2026.

πŸ’° The company reported second-quarter revenue of USD 5.44 billion, marking a 7.50% year-over-year increase.

πŸ“ˆ Adjusted earnings per share for the second quarter reached USD 0.86, beating the consensus estimate of USD 0.83.

🎯 Third-quarter adjusted earnings guidance is set between USD 0.80 and USD 0.82 per share.

πŸ‘€ Joseph M. Fitzgerald was appointed as executive vice president and chief operating officer effective January 1, 2027.

πŸ“‰ Analysts have a wide range of price targets, with recent reductions noted by brokerages like Leerink Partners.

πŸ₯ The company operates in the Healthcare / Medical devices sector with a market capitalization of USD 66.2 billion.

Bullish Signals
  • Boston Scientific reported second-quarter revenue of USD 5.44 billion, a significant 7.50% year-over-year increase.
  • The company beat analyst expectations for the second quarter with adjusted earnings per share of USD 0.86 versus a consensus of USD 0.83.
  • Second-quarter revenue of USD 5.44 billion exceeded the analyst estimate of USD 5.38 billion.
Risk Factors
  • Analyst price targets remain wide and volatile, with Leerink Partners recently cutting its target from USD 60.00 to USD 55.00.
  • The average 12-month analyst target of USD 68.23 is significantly lower than the current stock price, indicating mixed confidence in the full-year path.
Full Analysis
Boston Scientific is preparing to release its third-quarter financial results before the market opens on October 28, 2026. The company's stock was trading at EUR 40.89 on October 26, 2026, reflecting a modest gain of 0.70% against the previous close. This pre-earnings activity sets the stage for investor anticipation regarding the upcoming quarterly performance report. The company recently reported strong second-quarter results with revenue reaching USD 5.44 billion, representing a 7.50% year-over-year increase. Adjusted earnings per share hit USD 0.86, surpassing the consensus estimate of USD 0.83, while total revenue exceeded analyst expectations of USD 5.38 billion. These figures demonstrate solid operational growth ahead of the Q3 disclosure. For the third quarter, Boston Scientific has provided adjusted earnings guidance ranging from USD 0.80 to USD 0.82 per share. This guidance range sits above the current analyst consensus estimate of approximately USD 0.746 per share and the projected revenue of USD 5.10 billion. The company also appointed Joseph M. Fitzgerald as executive vice president and chief operating officer, effective January 1, 2027.